- Conditions
- Influenza Immunization
- Interventions
- Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 310
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza, Healthy Volunteers
- Interventions
- Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more
- Conditions
- Healthy Participants
- Interventions
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 37
- States / cities
- Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
- Conditions
- Healthy Participants
- Interventions
- MK-1406 Injection
- Combination Product
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Miami Lakes, Florida • Spartanburg, South Carolina
- Conditions
- Influenza
- Interventions
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,561 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 27 more
- Conditions
- Influenza, Hepatitis A, Typhoid, Healthy Adults
- Interventions
- Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Influenza
- Interventions
- Placebo, Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more
- Conditions
- Influenza, Respiratory Tract Infections
- Interventions
- Enhanced texts with Callback by a Person, Enhanced Bidirectional Texts
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 246,295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Pandemic H5N1 Influenza
- Interventions
- Adjuvanted H5N1 pandemic influenza vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 979 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Miami, Florida • St Louis, Missouri • Austin, Texas
- Conditions
- Respiratory Syncytial Virus
- Interventions
- MEDI7510, IIV, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 1,900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 30
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 27 more
- Conditions
- Influenza
- Interventions
- VRC-FLUNPF081-00-VP (HA-F A/Sing), VRC-FLUDNA082-00-VP (DNA A/Sing)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- V116, QIV, Matching Placebo for V116
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,080 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more
- Conditions
- Influenza, Healthy
- Interventions
- Fluzone®, FluMist®
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Months to 10 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pneumococcal Infections
- Interventions
- V114, QIV, Matching Placebo for V114
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Quadrivalent influenza vaccine, Ofatumumab, iDMT
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri
- Conditions
- Influenza
- Interventions
- VAX128, Placebo
- Biological
- Lead sponsor
- VaxInnate Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Miami, Florida • Lenexa, Kansas
- Conditions
- Influenza
- Interventions
- GSK2340274A, GSK2340273A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,048 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 25
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more
- Conditions
- Influenza, Human, SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV, Normal saline placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 644 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 30
- States / cities
- Lake Forest, California • Tustin, California • Walnut Creek, California + 22 more
- Conditions
- Healthy
- Interventions
- HAI-05 Influenza Vaccine, Saline
- Biological · Other
- Lead sponsor
- Fraunhofer, Center for Molecular Biotechnology
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Wichita, Kansas • Kansas City, Missouri
- Conditions
- Decision-Making, Patient Care, Treatment Decisions
- Interventions
- Influenza vaccine, Placebo
- Biological · Other
- Lead sponsor
- University of Arkansas, Fayetteville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Fayetteville, Arkansas • Albuquerque, New Mexico • Roanoke, Virginia
- Conditions
- Depression, Healthy
- Interventions
- Influenza Vaccine
- Biological
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Haemophilus Influenzae Type b, Neisseria Meningitidis
- Interventions
- GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 4,432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
- Conditions
- COVID-19 Immunization, Influenza Immunization
- Interventions
- IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl)
- Biological · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 980 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 368 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more